Abstract
Active surveillance is evolving as a management strategy for favorable-risk prostate cancer. Further study is needed to determine the safety of surveillance for specific subgroups of patients, and to clarify the role of genomic markers and image-guided biopsy.
Original language | English (US) |
---|---|
Pages (from-to) | 909-911 |
Number of pages | 3 |
Journal | European Urology |
Volume | 70 |
Issue number | 6 |
DOIs | |
State | Published - Dec 1 2016 |
ASJC Scopus subject areas
- Urology